27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
ObjectivesIdentifying modifiable factors that shape cognitive aging trajectories is a central goal in aging research. 5 key findings →
Design: cross-sectional Participants: 4,140 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia poses a significant global health challenge for both clinicians and patients, impacting millions of individuals worldwide, yet its early diagnosis remains underexplored. 2 key findings →
Design: meta-analysis Participants: 415 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
One-third of adults with neurological conditions in China have low health literacy, with pronounced socioeconomic and geographic disparities. 4 key findings →
Design: cross-sectional Participants: 1,120 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Thirty-three studies were included, most published after 2019 (72.7%). 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Despite comprising the largest segment of the sexual minority population and experiencing unique stressors and health disparities, bi+ dementia caregivers remain underrepresented in health and caregiving research. 3 key findings →
Design: cross-sectional Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study reveals a critical disconnect between moderate dementia knowledge and the application of this knowledge into perceived clinical competence. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Black caregivers reported shorter sleep duration but lower daily pain than White caregivers. 5 key findings →
Participants: 210 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the n = 180 participants recruited, n = 77 participated in this study, n = 37 caregivers and n = 40 non-caregivers. 5 key findings →
Participants: 180 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found comparable associations between dementia and PRS when comparing a C+T method with only 15 SNPs and PRS derived from Bayesian models that include > 800,000 SNPs (HR 5e‐08 = 1.18, 95% CI: 1.08–1.28; HR CSx = 1.17, 95% CI: 1.07−1.27). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 53 stakeholders participated in focus groups and engagement sessions. 5 key findings →
Participants: 53 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundCholinesterase inhibitors (ChEIs) are cornerstones of the symptomatic treatment of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) and are also prescribed for vascular dementia (VaD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) and related dementias (ADRD) are neurodegenerative conditions that cause gradual deterioration of cognition, memory and language in the elderly. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.002). A sharp transient increase occurred in 2020, attributable to pandemic-related factors including disproportionate COVID-19 mortality among older adults with neurodegenerative conditions, care disruptions, and changes in death-certificate coding practices. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Foundation models (FMs) are entering Alzheimer's disease and related dementias (ADRD), yet bedside impact remains limited. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Seventeen articles were included. People with dementia from ethnic minority groups report lower quality care received. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study included seven healthcare workers, five participants with dementia and their caregivers, and 10 persons without dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Persistent racial disparities in dementia raise concerns regarding the validity and generalizability of existing prognostic models across diverse populations. 2 key findings →
Participants: 55,004 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
INTRODUCTIONThe number of people living with dementia in many African countries is anticipated to treble by 2050. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundMultimorbidity is common among U.S. skilled nursing facilities (SNFs) residents and complicates pharmacologic management, yet real-world evidence on treatment patterns in this population remains limited. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
NST showed stable cross-cohort structure (Mantel r = 0.71-0.77) and differentiated MCI (d = -0.39) and AD biomarker status (d = -0.23). 4 key findings →
Design: longitudinal study Participants: 1,479 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Recorded PD-related mortality was lower among Black than White adults, whereas AD-related mortality showed no statistically significant racial difference. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This nationwide study provides epidemiological data on dementia and MCI among adults aged ≥ 60 years across all 12 administrative regions of Morocco. 1 key finding →
Design: cross-sectional Participants: 1,662 Evidence: low
Full summary, score breakdown and related studies → Original source
Memory IIV may be more closely linked to hippocampal white matter, while mean memory performance may better reflect hippocampal volume. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study reports the prevalence of CF among elderly hypertensive residents of a community in Inner Mongolia. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Drama therapy is in an accelerated growth phase, with substantial scholarly expansion expected over the next two decades. 4 key findings →
Participants: 785 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →